Antigen News and Research

RSS

Studies show prognostic value for circulating tumor cells in advanced prostate and breast cancer

Menarini Silicon Biosystems, the pioneer of liquid biopsy and single cell technologies, announced today that results from a new study presented at the virtual 2020 meeting of the American Society of Clinical Oncology suggest that circulating tumor cell counts may be useful in determining long-term prognosis and guiding treatment selection in patients with metastatic castrate sensitive prostate cancer.

10 Jun 2020

Immune system can be re-wired to prevent attack of healthy cells, study finds

The body's immune system can be re-wired to prevent it from recognizing its own proteins which, when attacked by the body, can cause autoimmune diseases like multiple sclerosis, a significant new study by UK scientists has found.

9 Jun 2020

Avacta provides update on COVID-19 antigen diagnostic test development with Adeptrix

Avacta Group plc is pleased to announce that a BAMS™ diagnostic test for COVID-19, being developed with Adeptrix, has reached the prototype stage.

From Avacta Life Sciences Ltd. 9 Jun 2020

Anti-RBD antibodies shown to neutralize active SARS-CoV-2

A new study published on the preprint server bioRxiv* in June 2020 reports the discovery of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in samples from healthy donors, collected before the pandemic. These antibodies are capable of inhibiting the binding of the spike protein of the virus to the angiotensin-converting enzyme 2 (ACE2) molecule and can neutralize active infection of cells in culture.

9 Jun 2020

Health disparities negatively impact various groups of people

Certain illnesses and diseases have the ability to affect various groups of people in detrimental ways.

8 Jun 2020

Synthetic monoclonal antibodies effectively neutralize SARS-CoV-2 in laboratory conditions

In a new study available on the preprint server bioRxiv*, a multinational research group demonstrated how monoclonal antibodies strongly inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro at even sub-nanomolar concentrations. This makes them a prime candidate for the treatment of coronavirus disease (COVID-19).

8 Jun 2020

SARS-CoV-2 invasion of central nervous system through olfactory tract

As the COVID-19 pandemic continues to claim lives throughout the world, the evidence is mounting that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects the respiratory tract as well as the central nervous system. Now, a new study by German researchers published on the preprint server bioRxiv in June 2020 describes various neurological manifestations of COVID-19, as well as the underlying pathophysiology.

7 Jun 2020

A SARS-CoV-2 antibody magnetic immuno-detection test

A new report, released on the preprint server bioRxiv by researchers at the Fraunhofer Institute for Molecular Biology and Applied Ecology, describes the development of an innovative serologic test that could provide a fast, easy, and inexpensive method of detecting high titers of antibody in the serum of SARS-CoV-2 infected people.

4 Jun 2020

Designing a prototype spike protein vaccine for SARS-CoV-2

A recent study published on the preprint server bioRxiv in June 2020 reports the development of a prototype vaccine containing multiple antigenic sites, based on the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the current COVID-19 pandemic. If successful, this could lead to the development of an effective, non-allergenic vaccine that induces both humoral and cellular immunity.

4 Jun 2020

Immune responsive nanoparticles for COVID-19 vaccine delivery

Analytik reports how the renowned Quadram Institute has invested in a ZetaView Nanoparticle Tracking Analyser to help them develop a new approach for vaccine delivery based on engineering the natural ability of resident gut bacteria to generate nanoparticle sized Outer Membrane Vesicles.

From Analytik Ltd 4 Jun 2020

Tumors cause disruption of the immune system throughout the body, study finds

Cancer treatment has advanced with the advent of immunotherapies that, in some cancers, can overcome tumors' ability to evade the immune system by suppressing local immune responses.

3 Jun 2020

A vectored vaccine candidate against SARS-CoV-2

The current pandemic of COVID-19 is caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), a betacoronavirus similar to that which caused the SARS-CoV and MERS-CoV earlier. Scientists are pursuing therapeutic drugs and vaccines to counter the relentless spread of the virus, but so far, none has been established to be effective. However, several are in clinical trials in various parts of the world.

2 Jun 2020

Journal publication supports Synlogic’s first clinical immuno-oncology program, SYNB1891

Synlogic, Inc., a clinical-stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the publication in Nature Communications of preclinical data supporting its first clinical immuno-oncology program, SYNB1891, which is being evaluated in Phase 1 clinical trial in patients with advanced solid tumors or lymphoma.

2 Jun 2020

At-home finger prick COVID-19 antibody testing

The best way to estimate the actual prevalence of COVID-19 in the population is by antibody testing. A new study by scientists at Enable Biosciences and published on the preprint server medRxiv* in May 2020 reports the development of fast and sensitive antibody testing kits designed for at-home use. This could significantly boost the measurement of population prevalence of this infection and help understand whether it confers immunity to reinfection.

2 Jun 2020

Blood test may predict a patient’s response to prostate cancer treatment

A team of researchers at The Institute of Cancer Research (ICR) in London found that the test can detect traces of cancer DNA in the bloodstream. The liquid biopsy could also identify the patients who are more likely to relapse.

1 Jun 2020

Genetic screening could be effective at detecting undiagnosed cases of prostate cancer

Genetic screening for prostate cancer in GP surgeries could be effective at picking up otherwise undiagnosed cases of the disease, a new pilot study shows.

31 May 2020

New immunotherapy for metastatic non-small cell lung cancer shows promise in clinical trial

A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System.

30 May 2020

Clinical trial shows anti-tumor responses in metastatic castration-resistant prostate cancer patients

The preliminary results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC protein degrader, demonstrates clinical evidence of anti-tumor responses in patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed prior therapy.

29 May 2020

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Researchers investigate possible causes of high COVID-19 mortality in Italy

On March 11th, 2020 the World Health Organization declared Coronavirus disease (COVID-19) a pandemic.

29 May 2020

Antigen News and Research

Studies show prognostic value for circulating tumor cells in advanced prostate and breast cancer

Immune system can be re-wired to prevent attack of healthy cells, study finds

Avacta provides update on COVID-19 antigen diagnostic test development with Adeptrix

Anti-RBD antibodies shown to neutralize active SARS-CoV-2

Health disparities negatively impact various groups of people

Synthetic monoclonal antibodies effectively neutralize SARS-CoV-2 in laboratory conditions

SARS-CoV-2 invasion of central nervous system through olfactory tract

A SARS-CoV-2 antibody magnetic immuno-detection test

Designing a prototype spike protein vaccine for SARS-CoV-2

Immune responsive nanoparticles for COVID-19 vaccine delivery

Tumors cause disruption of the immune system throughout the body, study finds

A vectored vaccine candidate against SARS-CoV-2

Journal publication supports Synlogic’s first clinical immuno-oncology program, SYNB1891

At-home finger prick COVID-19 antibody testing

Blood test may predict a patient’s response to prostate cancer treatment

Genetic screening could be effective at detecting undiagnosed cases of prostate cancer

New immunotherapy for metastatic non-small cell lung cancer shows promise in clinical trial

Clinical trial shows anti-tumor responses in metastatic castration-resistant prostate cancer patients

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

Researchers investigate possible causes of high COVID-19 mortality in Italy

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest Life Science News